友情提示：以下期刊信息可能会有更新，仅供参考，请在投稿前自行登录期刊官网仔细核实。
期刊名
JOURNAL OF PATHOLOGY
J PATHOL
ISSN / eISSN
0022-3417 / 1096-9896
目标和范围
The Journal of Pathology aims to serve as a translational bridge between basic biomedical science and clinical medicine with particular emphasis on, but not restricted to, tissue based studies. The main interests of the Journal lie in publishing studies that further our understanding the pathophysiological and pathogenetic mechanisms of human disease.
The Journal welcomes investigative studies on human tissues, in vitro and in vivo experimental studies, and investigations based on animal models with a clear relevance to human disease, including transgenic systems. In general, hypothesis driven studies that appropriately employ multiple investigative techniques are preferred over those that rely on a single methodology.
As well as original research papers, the Journal seeks to provide rapid publication in a variety of other formats, including editorials, review articles, commentaries and perspectives and other features, both contributed and solicited.
Purely descriptive papers on diagnostic pathology (including case reports and prognostic papers without mechanistic and experimental insights) are not considered central to the Journal’s purpose. Correspondence relating to papers published in the Journal will be considered, but only if of general interest. Such correspondance may be published in online versions only, at the Editor's discretion.
In determining content, the primary considerations are excellence, relevance and novelty. As the journal of The Pathological Society, it seeks to reflect the broad scientific interests of the Society’s membership but its ethos, authorship, content and purpose are those expected of a leading publication in the international scientific literature.
The Journal welcomes investigative studies on human tissues, in vitro and in vivo experimental studies, and investigations based on animal models with a clear relevance to human disease, including transgenic systems. In general, hypothesis driven studies that appropriately employ multiple investigative techniques are preferred over those that rely on a single methodology.
As well as original research papers, the Journal seeks to provide rapid publication in a variety of other formats, including editorials, review articles, commentaries and perspectives and other features, both contributed and solicited.
Purely descriptive papers on diagnostic pathology (including case reports and prognostic papers without mechanistic and experimental insights) are not considered central to the Journal’s purpose. Correspondence relating to papers published in the Journal will be considered, but only if of general interest. Such correspondance may be published in online versions only, at the Editor's discretion.
In determining content, the primary considerations are excellence, relevance and novelty. As the journal of The Pathological Society, it seeks to reflect the broad scientific interests of the Society’s membership but its ethos, authorship, content and purpose are those expected of a leading publication in the international scientific literature.
研究方向
病理学
肿瘤学
CiteScore
15.30
查看趋势图
CiteScore 学科排名
| 类别 | 分区 | 排名 |
|---|---|---|
| Medicine - Pathology and Forensic Medicine | Q1 | #4/193 |
Web of Science 核心合集
| Science Citation Index Expanded (SCIE) | Social Sciences Citation Index (SSCI) |
|---|---|
| Indexed | - |
| 类别 (Journal Citation Reports 2023) | 分区 |
|---|---|
| ONCOLOGY - SCIE | Q1 |
| PATHOLOGY - SCIE | Q1 |
H-index
168
出版国家或地区
ENGLAND
出版商
John Wiley and Sons Ltd
出版周期
Monthly
出版年份
1969
年文章数
121
Open Access
NO
通讯方式
JOHN WILEY & SONS LTD, THE ATRIUM, SOUTHERN GATE, CHICHESTER, ENGLAND, W SUSSEX, PO19 8SQ
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now